Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Nature Medicine

Topics

Medicine

Cancer Oncology

Internal Medicine

Surgery

Nivolumab

Show all topics

DOI

10.1038/s41591-020-0805-8

Other Formats

PDF